person · Reporting owner

Ho Maykin

Disclosed activity across 5 companies

Tapewire entity: 35961
SEC CIK: 0001646395

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	Director	June 18, 2026	June 23, 2026
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	June 02, 2026	June 04, 2026
KYNTRA BIO, INC.KYNB · Entity 7431	Director	June 12, 2026	June 17, 2026
Neumora Therapeutics, Inc.NMRA · Entity 6115	Director	May 27, 2026	May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	19,848	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 19,848
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	2,927	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18	Direct	14,950	Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

BIOMARIN PHARMACEUTICAL INC

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	35,500	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 35,500 F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on June 2, 2026. Price not applicable.

KYNTRA BIO, INC.

Report date June 12, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11	Direct	7,000	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Neumora Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26	Direct	80,000	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PAREXEL INTERNATIONAL CORP

Report date September 29, 2017 · Filed October 04, 2017

Section 16 reporting ended · disclosed 2017-10-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-09-29 transaction · row 1 1 source row Row 1 · 2017-09-29 · Disposition to issuer · Disposed 6,612 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 21:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	14,950	$0.00 Strike: $34.16	$0.00	Disclosure SEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,927	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2026 Filed Jun 17, 2026 23:43 UTC	KYNTRA BIO, INC. KYNB · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $7.13	$0.00	Disclosure SEC source: 0001646395-26-000002 · form4-06172026_110643.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. Read SEC document
June 02, 2026 Filed Jun 4, 2026 22:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	7,490	$0.00	$0.00	Disclosure SEC source: 0001628280-26-040918 · wk-form4_1780610870.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 F1 · price: Restricted stock units granted on June 2, 2026. Price not applicable. Read SEC document
May 27, 2026 Filed May 29, 2026 20:21 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	80,000	$0.00 Strike: $1.86	$0.00	Disclosure SEC source: 0001610717-26-000169 · form4.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-05-26 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000053 · wk-form4_1750710074.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000053 · wk-form4_1750710074.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	15,768	$0.00 Strike: $35.50	$0.00	Disclosure SEC source: 0001439222-25-000053 · wk-form4_1750710074.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:21 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000053 · wk-form4_1750710074.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,816 Underlying: Common stock · 2,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:20 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	120,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001415889-25-015989 · form4-06062025_080642.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of four equal quarterly installments measured from the date of grant or the date of the next annual meeting of stockholders, subject to the reporting person's continued service at each applicable vest date. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	80,000	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 7 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-05-27 F4 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	28,571	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 6 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F3 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	27,802	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 5 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F3 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	95,586	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,586 Underlying: Common Stock · 95,586 shares Expires 2031-04-23 F3 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	28,571	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	27,802	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	95,586	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-079919 · ownership.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,586 shares Expires 2031-04-23 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 20, 2025 Filed May 22, 2025 20:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	6,650	$0.00	$0.00	Disclosure SEC source: 0001048477-25-000072 · wk-form4_1747947452.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,010 F1 · price: Restricted stock units granted on May 20, 2025. Price not applicable. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	28,571	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 6 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	27,802	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 5 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	95,586	Not disclosed Strike: $1.69	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,586 Underlying: Common Stock · 95,586 shares Expires 2031-04-23 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	28,571	Not disclosed Strike: $9.95	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,571 shares Expires 2034-06-13 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	27,802	Not disclosed Strike: $17.00	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,802 shares Expires 2033-09-14 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Disposition to issuerStock Option (Right to Buy) · Derivative	95,586	Not disclosed Strike: $2.51	Not disclosed	Disclosure SEC source: 0000950170-25-022327 · ownership.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,586 shares Expires 2031-04-23 F2 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	11,774	$0.00 Strike: $42.45	$0.00	Disclosure SEC source: 0001439222-24-000104 · wk-form4_1719259794.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000104 · wk-form4_1719259794.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:18 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	28,571	$0.00 Strike: $9.95	$0.00	Disclosure SEC source: 0001610717-24-000338 · form4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,571 Underlying: Common Stock · 28,571 shares Expires 2034-06-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:18 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantCommon Stock	20,100	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000338 · form4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:19 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000081 · wk-form4_1718659159.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:19 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000081 · wk-form4_1718659159.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 05, 2024 Filed Jun 7, 2024 00:00 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $1.21	$0.00	Disclosure SEC source: 0001415889-24-015857 · form4-06062024_080612.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
May 21, 2024 Filed May 23, 2024 21:30 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,720	$0.00	$0.00	Disclosure SEC source: 0001048477-24-000104 · wk-form4_1716499826.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,360 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document
September 14, 2023 Filed Sep 18, 2023 21:50 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	27,802	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001610717-23-000281 · form4.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,802 Underlying: Common Stock · 27,802 shares Expires 2033-09-13 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:37 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock unit · Derivative	4,975	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000095 · wk-form4_1687552637.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:37 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	4,975	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000095 · wk-form4_1687552637.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	18,958	$0.00 Strike: $26.56	$0.00	Disclosure SEC source: 0001439222-23-000077 · wk-form4_1686860613.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,958 Underlying: Common stock · 18,958 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000077 · wk-form4_1686860613.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,388 Underlying: Common stock · 3,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 08, 2023 Filed Jun 9, 2023 23:54 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	6,225	$17.68	$110,058.00	Disclosure SEC source: 0001209191-23-036078 · doc4.xml · nonDerivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,501 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.48 to $17.865. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 08, 2023 Filed Jun 9, 2023 23:54 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	2,295	$16.79	$38,533.05	Disclosure SEC source: 0001209191-23-036078 · doc4.xml · nonDerivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,726 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.48 to $17.31. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:54 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	12,666	$0.00 Strike: $17.13	$0.00	Disclosure SEC source: 0001209191-23-036078 · doc4.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,666 Underlying: Common Stock · 12,666 shares Expires 2033-06-06 F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:54 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	8,289	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036078 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,021 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
May 23, 2023 Filed May 24, 2023 22:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,190	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031970 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,640 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document
June 21, 2022 Filed Jun 23, 2022 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	29,307	$0.00 Strike: $18.09	$0.00	Disclosure SEC source: 0001439222-22-000063 · wf-form4_165601500669941.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 Underlying: Common stock · 29,307 shares Expires 2032-06-21 F3 · derivative.exercise_date: This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023. Read SEC document
June 21, 2022 Filed Jun 23, 2022 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock unit · Derivative	4,975	$0.00	$0.00	Disclosure SEC source: 0001439222-22-000063 · wf-form4_165601500669941.xml · derivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Underlying: Common stock · 4,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:13 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	25,684	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001209191-22-038616 · doc4.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,684 Underlying: Common Stock · 25,684 shares Expires 2032-06-15 F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:13 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	15,777	$0.00	$0.00	Disclosure SEC source: 0001209191-22-038616 · doc4.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,732 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
May 24, 2022 Filed May 27, 2022 00:57 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,980	$0.00	$0.00	Disclosure SEC source: 0001567619-22-011792 · doc1.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document
May 20, 2022 Filed May 24, 2022 20:11 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock unit · Derivative	1,585	$0.00	$0.00	Disclosure SEC source: 0001439222-22-000050 · wf-form4_165342305911473.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested F2 · derivative.expiration_date: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.